Board Changes

Phytopharm PLC
09 January 2007


Company Contact:                         U.K. Investor Relations Contact:

Phytopharm plc                           Financial Dynamics

Dr Daryl Rees                            David Yates

Mr Piers Morgan                          Ben Atwell
                                         
[phone]                         [phone]

www.phytopharm.com


                                  Board Changes


GODMANCHESTER, Cambridgeshire, U.K. (9th January 2007) - Phytopharm plc (LSE:
PYM; NASDAQBB: PHYOF; PHYOY) ('Phytopharm' or the 'Company') today announces a
number of planned changes to its senior management team ahead of the next phase
in its development.


Dr Richard Dixey, Phytopharm's co-founder who has led the Company over the last
ten years, is stepping down as Chief Executive Officer and Board Director.  He
is succeeded as Chief Executive Officer by Dr Daryl Rees who has served as
Phytopharm's Chief Operating Officer for the past six years.  Dr Rees will focus
on generating growth and value from Phytopharm's strong product portfolio, in
particular its Hoodia gordonii functional food obesity programme which is
partnered with Unilever and its Myogane and Cogane pharmaceutical neurological
products, which are currently in Phase I and II clinical development
respectively.


Phytopharm is also pleased to announce today the appointment of Mr Piers Morgan
as Chief Financial Officer and Board Director. Mr Morgan has an MA in Law and
Management Studies from Cambridge University and is a Chartered Accountant.  He
worked at Close Brothers Corporate Finance on a wide variety of Equity Capital
Market and Mergers & Acquisitions transactions and was a founding director of
the Life Sciences Mergers & Acquisitions team at Ernst & Young.  In 2000, he
joined Arrow Therapeutics Limited as Finance Director, raising significant
finance through private equity, debt and grants.  In 2005, he moved to Paris to
become Chief Financial Officer of BioAlliance SA, where he led the successful
flotation of the company on Euronext Paris.  There are no further disclosures to
be made under paragraphs 9.6.13R of the Listing Rules and 3.1.2R of the
Disclosures Rules in respect of Mr Morgan.


All Board changes are with immediate effect and form part of the planned
restructuring of the Board.


Dr Richard Dixey has confirmed that he has no current intention to sell any
shares in Phytopharm and he and Chakra Limited (a Company which Dr Dixey holds
50 per cent of the share capital) have agreed not to dispose of their interests
in the ordinary shares of the Company for a period of 6 months from today's
date. For a further period of 3 months, any disposals of their interests in the
ordinary shares of the Company will be through the Company's appointed
stockbroker only.


Commenting, Dr Paul Whitney, Chairman, said:

'On behalf of the Board of Phytopharm and myself personally, I would like to
thank Richard Dixey for his enthusiasm, energy and pivotal contribution to the
development of Phytopharm over the past ten years.  We wish him well in his
future activities.'


Dr Richard Dixey added:

'I have thoroughly enjoyed my time leading Phytopharm and I am delighted to be
handing over the CEO's role to Daryl Rees.  He has been instrumental in the
success of Phytopharm's product development to date and with the strong addition
of Piers Morgan to the Board as CFO, I believe the Company is well placed for
much-deserved success.'

                                     -ENDS-


NOTES TO EDITORS


Phytopharm plc


Phytopharm is a pharmaceutical development and functional food company whose
product leads are generated from medicinal plant extracts.  The Company's
strategy is to develop these products through 'proof of principle' clinical
testing, and then secure partners for late stage development, sales and
marketing.  This business model generates a lean cash burn and all laboratory,
manufacturing and clinical work is outsourced to specialists while core
competencies such as strategy and management are kept in-house.  This
operational structure allows access to advanced research techniques whilst
maintaining low fixed overheads and a lower development cost structure.


More information concerning Phytopharm's activities can be found on its website
at http://www.phytopharm.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange